id	sid	eid	entity	type
dti-3213	1	1	dti	ORG
dti-3213	1	2	2024	CARDINAL
dti-3213	1	3	18	CARDINAL
dti-3213	1	4	105	CARDINAL
dti-3213	1	5	1177-3928	CARDINAL
dti-3213	1	6	10.33393	CARDINAL
dti-3213	1	7	1177-3928	CARDINAL
dti-3213	1	8	2024	CARDINAL
dti-3213	2	1	4.0	CARDINAL
dti-3213	4	1	italy	GPE
dti-3213	4	2	carlotta galeone 1,2	PERSON
dti-3213	4	3	federica turati3	PERSON
dti-3213	4	4	massimo nicolò 4	PERSON
dti-3213	4	5	5	CARDINAL
dti-3213	4	6	6,7	CARDINAL
dti-3213	4	7	laura bianchino8	PERSON
dti-3213	4	8	8	CARDINAL
dti-3213	4	9	paolo	PERSON
dti-3213	4	10	1bicocca	CARDINAL
dti-3213	4	11	università degli studi di milano-bicocca	GPE
dti-3213	4	12	milan italy 2biostatistics & outcome	ORG
dti-3213	4	13	milan	GPE
dti-3213	5	1	university of milan	ORG
dti-3213	5	2	milan	GPE
dti-3213	5	3	italy	GPE
dti-3213	6	1	4clinica	GPE
dti-3213	6	2	ospedale policlinico	ORG
dti-3213	6	3	san martino	GPE
dti-3213	6	4	genoa	GPE
dti-3213	6	5	italy	GPE
dti-3213	6	6	rome	GPE
dti-3213	7	1	6department	CARDINAL
dti-3213	7	2	university of milan	ORG
dti-3213	7	3	milan italy 7eye	ORG
dti-3213	7	4	multimedica	GPE
dti-3213	7	5	milan	GPE
dti-3213	7	6	italy 8roche	GPE
dti-3213	7	7	s.p.a.	GPE
dti-3213	8	1	university of udine	ORG
dti-3213	8	2	udine	PERSON
dti-3213	8	3	italy 10iemo	ORG
dti-3213	8	4	istituto europeo di microchirurgia	PERSON
dti-3213	8	5	udine italy	ORG
dti-3213	8	6	itc	ORG
dti-3213	8	7	italy	GPE
dti-3213	8	8	ranibizumab	PERSON
dti-3213	8	9	anti-vegf	PERSON
dti-3213	10	1	cst	ORG
dti-3213	10	2	baseline to 1 year	DATE
dti-3213	10	3	week 52	DATE
dti-3213	10	4	week 48	DATE
dti-3213	13	1	itc	ORG
dti-3213	13	2	513	CARDINAL
dti-3213	13	3	263	CARDINAL
dti-3213	14	1	1 year	DATE
dti-3213	14	2	faricimab	ORG
dti-3213	14	3	cst	ORG
dti-3213	15	1	cst	ORG
dti-3213	15	2	−71.5 μm	MONEY
dti-3213	16	1	itc	ORG
dti-3213	16	2	cst	ORG
dti-3213	17	1	july 18, 2024	DATE
dti-3213	17	2	november 13	DATE
dti-3213	17	3	2024	CARDINAL
dti-3213	17	4	december 12	DATE
dti-3213	17	5	2024	CARDINAL
dti-3213	17	6	carlotta galeone	PERSON
dti-3213	18	1	4-8)	DATE
dti-3213	19	1	the last couple of decades	DATE
dti-3213	19	2	anti-vegf	NORP
dti-3213	20	1	1-3	CARDINAL
dti-3213	21	1	age 55	DATE
dti-3213	21	2	1	CARDINAL
dti-3213	23	1	2024	CARDINAL
dti-3213	24	1	1177-3928	CARDINAL
dti-3213	24	2	9-17	DATE
dti-3213	25	1	italy	GPE
dti-3213	25	2	4.6	CARDINAL
dti-3213	25	3	1,000	CARDINAL
dti-3213	25	4	18	CARDINAL
dti-3213	26	1	anti-vegf administration	ORG
dti-3213	27	1	bimonthly	DATE
dti-3213	28	1	three	CARDINAL
dti-3213	28	2	monthly	DATE
dti-3213	28	3	monthly	DATE
dti-3213	29	1	19	CARDINAL
dti-3213	30	1	bimonthly	DATE
dti-3213	30	2	bimonthly	DATE
dti-3213	30	3	at least 1 year	DATE
dti-3213	30	4	20	CARDINAL
dti-3213	30	5	21	CARDINAL
dti-3213	31	1	anti-vegf	PERSON
dti-3213	33	1	20-26	CARDINAL
dti-3213	34	1	2023	CARDINAL
dti-3213	34	2	the european medicines	ORG
dti-3213	34	3	ema	ORG
dti-3213	34	4	italian	NORP
dti-3213	34	5	agenzia	NORP
dti-3213	34	6	italiana del farmaco	ORG
dti-3213	34	7	27	CARDINAL
dti-3213	35	1	italy	GPE
dti-3213	35	2	ranibizumab	PERSON
dti-3213	35	3	bevacizumab	PERSON
dti-3213	35	4	28	CARDINAL
dti-3213	36	1	ranibizumab	PERSON
dti-3213	36	2	brolucizumab	PERSON
dti-3213	36	3	ema	ORG
dti-3213	36	4	648/96	CARDINAL
dti-3213	36	5	648/96	CARDINAL
dti-3213	36	6	the national health service	ORG
dti-3213	36	7	italy	GPE
dti-3213	36	8	italy	GPE
dti-3213	36	9	one	CARDINAL
dti-3213	36	10	29	CARDINAL
dti-3213	37	1	30	CARDINAL
dti-3213	37	2	6.0 mg	QUANTITY
dti-3213	37	3	16 weeks	DATE
dti-3213	37	4	334	CARDINAL
dti-3213	37	5	331	CARDINAL
dti-3213	37	6	every 8 weeks	DATE
dti-3213	37	7	337	CARDINAL
dti-3213	37	8	327	CARDINAL
dti-3213	38	1	weeks 40, 44	DATE
dti-3213	38	2	48	DATE
dti-3213	38	3	5.8	CARDINAL
dti-3213	38	4	95%	PERCENT
dti-3213	38	5	ci	PERSON
dti-3213	38	6	4.6	CARDINAL
dti-3213	38	7	7.1	CARDINAL
dti-3213	38	8	6.6	CARDINAL
dti-3213	38	9	95%	PERCENT
dti-3213	38	10	5.23 to	CARDINAL
dti-3213	38	11	7.8	CARDINAL
dti-3213	38	12	tenaya	GPE
dti-3213	39	1	0.7	CARDINAL
dti-3213	39	2	95%	PERCENT
dti-3213	39	3	−1.1	PERSON
dti-3213	39	4	2.5	CARDINAL
dti-3213	39	5	tenaya	GPE
dti-3213	39	6	0.0	CARDINAL
dti-3213	39	7	95%	PERCENT
dti-3213	39	8	1.8	CARDINAL
dti-3213	40	1	italian	NORP
dti-3213	40	2	31	CARDINAL
dti-3213	40	3	anti-vegf	ORG
dti-3213	40	4	italy	GPE
dti-3213	41	1	anti-vegf	NORP
dti-3213	41	2	one	CARDINAL
dti-3213	41	3	ranibizumab	PERSON
dti-3213	41	4	january 2017 and	DATE
dti-3213	41	5	november 2018	DATE
dti-3213	42	1	va 52 weeks	DATE
dti-3213	42	2	three	CARDINAL
dti-3213	44	1	52 weeks	DATE
dti-3213	44	2	1.0	CARDINAL
dti-3213	44	3	25th-75th	ORG
dti-3213	45	1	stratifying va	GPE
dti-3213	45	2	6	CARDINAL
dti-3213	45	3	the first year	DATE
dti-3213	45	4	median va improvement	FAC
dti-3213	45	5	3	CARDINAL
dti-3213	45	6	25th-75th	ORG
dti-3213	45	7	−1	CARDINAL
dti-3213	45	8	11	CARDINAL
dti-3213	45	9	2	CARDINAL
dti-3213	45	10	0	CARDINAL
dti-3213	45	11	25th-75th	ORG
dti-3213	45	12	0	CARDINAL
dti-3213	45	13	3-5	CARDINAL
dti-3213	45	14	0	CARDINAL
dti-3213	45	15	25th-75th	ORG
dti-3213	45	16	+9.0	PERSON
dti-3213	46	1	ipd	ORG
dti-3213	46	2	anti-vegf	NORP
dti-3213	46	3	2 mg	PERSON
dti-3213	46	4	bevacizumab	PERSON
dti-3213	46	5	ranibizumab	PERSON
dti-3213	46	6	italy	GPE
dti-3213	47	1	1 year	DATE
dti-3213	47	2	two	CARDINAL
dti-3213	47	3	anti-vegf	PERSON
dti-3213	48	1	baseline to 1 year	DATE
dti-3213	48	2	week 52	DATE
dti-3213	48	3	week 48	DATE
dti-3213	48	4	etdrs	ORG
dti-3213	48	5	cst	ORG
dti-3213	49	1	ipd	ORG
dti-3213	49	2	30	CARDINAL
dti-3213	50	1	ipd	ORG
dti-3213	50	2	italian	NORP
dti-3213	50	3	31	CARDINAL
dti-3213	51	1	tenaya	GPE
dti-3213	53	1	31	CARDINAL
dti-3213	53	2	at least two	CARDINAL
dti-3213	53	3	at least one	CARDINAL
dti-3213	54	1	tenaya trials	ORG
dti-3213	55	1	30	CARDINAL
dti-3213	55	2	italian	NORP
dti-3213	55	3	caucasian	NORP
dti-3213	55	4	tenaya	GPE
dti-3213	55	5	cst	ORG
dti-3213	55	6	week 48	DATE
dti-3213	56	1	2024	CARDINAL
dti-3213	56	2	18	CARDINAL
dti-3213	56	3	107	CARDINAL
dti-3213	56	4	2024	CARDINAL
dti-3213	58	1	two	CARDINAL
dti-3213	60	1	32	CARDINAL
dti-3213	61	1	•	CARDINAL
dti-3213	61	2	cst	ORG
dti-3213	61	3	cst	ORG
dti-3213	61	4	• age	DATE
dti-3213	61	5	•	CARDINAL
dti-3213	61	6	•	CARDINAL
dti-3213	61	7	1	CARDINAL
dti-3213	61	8	2	DATE
dti-3213	61	9	3	CARDINAL
dti-3213	61	10	•	CARDINAL
dti-3213	61	11	irf	PERSON
dti-3213	62	1	•	CARDINAL
dti-3213	63	1	irf	PERSON
dti-3213	63	2	srf	ORG
dti-3213	64	1	chi-square	PERSON
dti-3213	65	1	one	CARDINAL
dti-3213	65	2	anova	ORG
dti-3213	65	3	cst	ORG
dti-3213	65	4	two	CARDINAL
dti-3213	66	1	31	CARDINAL
dti-3213	68	1	two	CARDINAL
dti-3213	68	2	0.05	CARDINAL
dti-3213	69	1	sas	ORG
dti-3213	69	2	9.4	CARDINAL
dti-3213	69	3	sas institute	ORG
dti-3213	69	4	cary	GPE
dti-3213	69	5	nc	GPE
dti-3213	70	1	405	CARDINAL
dti-3213	71	1	17	CARDINAL
dti-3213	71	2	anti-vegf	NORP
dti-3213	71	3	age ≥50 years	DATE
dti-3213	71	4	the date of the first	DATE
dti-3213	71	5	anti-vegf	NORP
dti-3213	71	6	1	CARDINAL
dti-3213	71	7	anti-vegf	PERSON
dti-3213	71	8	43	DATE
dti-3213	71	9	at least two	CARDINAL
dti-3213	71	10	81	DATE
dti-3213	72	1	tenaya	GPE
dti-3213	72	2	665	CARDINAL
dti-3213	72	3	152	CARDINAL
dti-3213	72	4	85	CARDINAL
dti-3213	72	5	65	DATE
dti-3213	72	6	cst	ORG
dti-3213	72	7	week 48	DATE
dti-3213	72	8	2	CARDINAL
dti-3213	73	1	513	CARDINAL
dti-3213	73	2	tenaya	GPE
dti-3213	73	3	263	CARDINAL
dti-3213	73	4	ranibizumab	PERSON
dti-3213	73	5	109	CARDINAL
dti-3213	74	1	1 year	DATE
dti-3213	74	2	week 48 and	DATE
dti-3213	74	3	52	DATE
dti-3213	75	1	cst	ORG
dti-3213	75	2	48-52	CARDINAL
dti-3213	75	3	97	CARDINAL
dti-3213	75	4	4	CARDINAL
dti-3213	75	5	cst	ORG
dti-3213	75	6	1 year	DATE
dti-3213	75	7	509	CARDINAL
dti-3213	75	8	166	CARDINAL
dti-3213	76	1	two	CARDINAL
dti-3213	77	1	cst	ORG
dti-3213	77	2	irf	PERSON
dti-3213	78	1	1	CARDINAL
dti-3213	78	2	2	CARDINAL
dti-3213	79	1	1	CARDINAL
dti-3213	79	2	iptw tenaya+lucerne	PERSON
dti-3213	79	3	513	CARDINAL
dti-3213	79	4	772.4 297.2 age	DATE
dti-3213	79	5	76	DATE
dti-3213	79	6	70-81	CARDINAL
dti-3213	79	7	78	DATE
dti-3213	79	8	73	CARDINAL
dti-3213	79	9	0.0007 77	PERCENT
dti-3213	79	10	71	CARDINAL
dti-3213	79	11	76	DATE
dti-3213	79	12	71-81	CARDINAL
dti-3213	79	13	0.040 0.601	CARDINAL
dti-3213	79	14	187	CARDINAL
dti-3213	79	15	36.5	CARDINAL
dti-3213	79	16	115	CARDINAL
dti-3213	79	17	43.7	CARDINAL
dti-3213	79	18	0.049 315.2	CARDINAL
dti-3213	79	19	40.8	CARDINAL
dti-3213	79	20	319.7	CARDINAL
dti-3213	79	21	40.1	CARDINAL
dti-3213	79	22	0.014	CARDINAL
dti-3213	79	23	326	CARDINAL
dti-3213	79	24	63.6	CARDINAL
dti-3213	79	25	148	CARDINAL
dti-3213	79	26	56.3	CARDINAL
dti-3213	79	27	457.2	CARDINAL
dti-3213	79	28	59.2	CARDINAL
dti-3213	79	29	477.6	CARDINAL
dti-3213	79	30	59.9	CARDINAL
dti-3213	79	31	faricimab	PERSON
dti-3213	79	32	2024	DATE
dti-3213	80	1	1177-3928	CARDINAL
dti-3213	80	2	iptw tenaya+lucerne	PERSON
dti-3213	80	3	1	CARDINAL
dti-3213	80	4	275	CARDINAL
dti-3213	80	5	54.6	CARDINAL
dti-3213	80	6	103	CARDINAL
dti-3213	80	7	40.9	CARDINAL
dti-3213	80	8	0.292	CARDINAL
dti-3213	80	9	0.001 395.7	CARDINAL
dti-3213	80	10	52.3	CARDINAL
dti-3213	80	11	406.4	CARDINAL
dti-3213	80	12	52.1	CARDINAL
dti-3213	81	1	0.005 0.951	CARDINAL
dti-3213	81	2	2)† 210	QUANTITY
dti-3213	81	3	41.7	CARDINAL
dti-3213	81	4	121	CARDINAL
dti-3213	81	5	48.0	CARDINAL
dti-3213	81	6	316.6	CARDINAL
dti-3213	81	7	41.8	CARDINAL
dti-3213	81	8	323.6	CARDINAL
dti-3213	81	9	41.5	CARDINAL
dti-3213	81	10	0.008	CARDINAL
dti-3213	81	11	3 19	CARDINAL
dti-3213	81	12	3.8	CARDINAL
dti-3213	81	13	28	CARDINAL
dti-3213	81	14	11.1	CARDINAL
dti-3213	81	15	45.1	CARDINAL
dti-3213	81	16	6.0	CARDINAL
dti-3213	81	17	49.4	CARDINAL
dti-3213	81	18	6.3	CARDINAL
dti-3213	81	19	9 11	TIME
dti-3213	81	20	no 276	CARDINAL
dti-3213	81	21	54.9	CARDINAL
dti-3213	81	22	84	CARDINAL
dti-3213	81	23	42.6	CARDINAL
dti-3213	81	24	0.026 0.004 359.2	CARDINAL
dti-3213	81	25	51.5	CARDINAL
dti-3213	81	26	371.8	CARDINAL
dti-3213	81	27	51.5	CARDINAL
dti-3213	81	28	0.998	CARDINAL
dti-3213	82	1	227	CARDINAL
dti-3213	82	2	45.1	CARDINAL
dti-3213	82	3	113	CARDINAL
dti-3213	82	4	57.4	CARDINAL
dti-3213	82	5	337.9	CARDINAL
dti-3213	82	6	48.5	CARDINAL
dti-3213	82	7	349.9	CARDINAL
dti-3213	82	8	48.5	CARDINAL
dti-3213	83	1	10	CARDINAL
dti-3213	83	2	75.3 75.4	CARDINAL
dti-3213	83	3	no 172	CARDINAL
dti-3213	83	4	34.0	CARDINAL
dti-3213	83	5	58	DATE
dti-3213	83	6	29.2	CARDINAL
dti-3213	83	7	0.236 0.217 233.4	MONEY
dti-3213	83	8	33.3	CARDINAL
dti-3213	83	9	264.5	CARDINAL
dti-3213	83	10	36.4	CARDINAL
dti-3213	83	11	0.055 0.211	CARDINAL
dti-3213	84	1	334	CARDINAL
dti-3213	84	2	66.0	CARDINAL
dti-3213	84	3	141	DATE
dti-3213	84	4	70.8	CARDINAL
dti-3213	84	5	468.2	CARDINAL
dti-3213	84	6	66.7	CARDINAL
dti-3213	84	7	461.7	CARDINAL
dti-3213	84	8	63.6	CARDINAL
dti-3213	84	9	70.8	CARDINAL
dti-3213	84	10	etdrs	ORG
dti-3213	84	11	±	CARDINAL
dti-3213	84	12	60.5	CARDINAL
dti-3213	84	13	57.1 ± 21.1 0.219 0.004 59.6 ±	QUANTITY
dti-3213	84	14	61.1 ±	CARDINAL
dti-3213	84	15	0.244	CARDINAL
dti-3213	86	1	irf = intraretinal fluid	PERSON
dti-3213	86	2	ranibizumab	PERSON
dti-3213	86	3	srf	ORG
dti-3213	87	1	2	CARDINAL
dti-3213	87	2	cst	ORG
dti-3213	87	3	iptw tenaya+lucerne	PERSON
dti-3213	87	4	76	DATE
dti-3213	88	1	70-81	CARDINAL
dti-3213	88	2	77	DATE
dti-3213	88	3	72-82	DATE
dti-3213	88	4	0.077 76	PERCENT
dti-3213	88	5	70-81	CARDINAL
dti-3213	88	6	76	DATE
dti-3213	88	7	70-80	DATE
dti-3213	88	8	0.030	CARDINAL
dti-3213	88	9	0.739	MONEY
dti-3213	88	10	184	CARDINAL
dti-3213	88	11	36.2	CARDINAL
dti-3213	88	12	80	DATE
dti-3213	88	13	48.2	CARDINAL
dti-3213	88	14	0.006 365.4	CARDINAL
dti-3213	88	15	39.4	CARDINAL
dti-3213	88	16	275.7	CARDINAL
dti-3213	88	17	40.4	CARDINAL
dti-3213	89	1	0.727	CARDINAL
dti-3213	89	2	325	CARDINAL
dti-3213	89	3	63.8	CARDINAL
dti-3213	89	4	86	DATE
dti-3213	89	5	51.8	CARDINAL
dti-3213	89	6	407.8	CARDINAL
dti-3213	89	7	60.6	CARDINAL
dti-3213	89	8	407.6	CARDINAL
dti-3213	89	9	59.7	CARDINAL
dti-3213	89	10	1	CARDINAL
dti-3213	89	11	274	CARDINAL
dti-3213	89	12	54.8	CARDINAL
dti-3213	89	13	76	DATE
dti-3213	89	14	47.2	CARDINAL
dti-3213	89	15	0.001 350.5	CARDINAL
dti-3213	89	16	53.1	CARDINAL
dti-3213	89	17	363.1	CARDINAL
dti-3213	89	18	54.2	CARDINAL
dti-3213	89	19	0.916	CARDINAL
dti-3213	89	20	2)† 207	CARDINAL
dti-3213	89	21	41.4	CARDINAL
dti-3213	89	22	63	DATE
dti-3213	89	23	39.1	CARDINAL
dti-3213	89	24	0.056 268.4	CARDINAL
dti-3213	89	25	40.7	CARDINAL
dti-3213	89	26	265.4	CARDINAL
dti-3213	89	27	39.6	CARDINAL
dti-3213	89	28	0.022	CARDINAL
dti-3213	89	29	3 19	CARDINAL
dti-3213	89	30	3.8	CARDINAL
dti-3213	89	31	22	DATE
dti-3213	89	32	13.7	CARDINAL
dti-3213	89	33	40.8	CARDINAL
dti-3213	89	34	6.2	CARDINAL
dti-3213	89	35	41.9	CARDINAL
dti-3213	89	36	6.5	CARDINAL
dti-3213	89	37	9 5	TIME
dti-3213	89	38	13.3 12.8 irf	QUANTITY
dti-3213	89	39	no 276	CARDINAL
dti-3213	89	40	55.2	CARDINAL
dti-3213	89	41	68	DATE
dti-3213	89	42	43.9	CARDINAL
dti-3213	90	1	0.004 343.4	CARDINAL
dti-3213	90	2	52.4	CARDINAL
dti-3213	90	3	342.6	CARDINAL
dti-3213	90	4	51.6	CARDINAL
dti-3213	90	5	0.755	CARDINAL
dti-3213	90	6	224	CARDINAL
dti-3213	90	7	44.8	CARDINAL
dti-3213	90	8	87	DATE
dti-3213	90	9	56.1	CARDINAL
dti-3213	90	10	311.8	CARDINAL
dti-3213	90	11	47.6	CARDINAL
dti-3213	90	12	321.8	CARDINAL
dti-3213	90	13	48.4	CARDINAL
dti-3213	90	14	9 11	TIME
dti-3213	90	15	18.0 18.8	CARDINAL
dti-3213	90	16	no 170	CARDINAL
dti-3213	90	17	33.9	CARDINAL
dti-3213	90	18	46	DATE
dti-3213	90	19	29.5	CARDINAL
dti-3213	91	1	0.309 219.3	CARDINAL
dti-3213	91	2	33.3	CARDINAL
dti-3213	91	3	242.6	CARDINAL
dti-3213	91	4	36.4	CARDINAL
dti-3213	92	1	0.065	CARDINAL
dti-3213	92	2	0.244	MONEY
dti-3213	93	1	332	CARDINAL
dti-3213	93	2	66.1	CARDINAL
dti-3213	93	3	110	CARDINAL
dti-3213	93	4	70.5	CARDINAL
dti-3213	93	5	438.8	CARDINAL
dti-3213	93	6	66.7	CARDINAL
dti-3213	93	7	424.4	CARDINAL
dti-3213	93	8	63.6	CARDINAL
dti-3213	93	9	7	CARDINAL
dti-3213	93	10	15.1 16.2 cst	QUANTITY
dti-3213	93	11	±	CARDINAL
dti-3213	93	12	359.8	CARDINAL
dti-3213	93	13	121.3	CARDINAL
dti-3213	93	14	0.021 366.3 ±	MONEY
dti-3213	93	15	144.3	CARDINAL
dti-3213	95	1	cst	ORG
dti-3213	95	2	irf = intraretinal fluid	PERSON
dti-3213	95	3	ranibizumab	PERSON
dti-3213	95	4	srf	ORG
dti-3213	96	1	1	CARDINAL
dti-3213	96	2	2024	CARDINAL
dti-3213	96	3	18	CARDINAL
dti-3213	96	4	109	CARDINAL
dti-3213	96	5	2024	CARDINAL
dti-3213	97	1	1 year	DATE
dti-3213	97	2	6.4	CARDINAL
dti-3213	97	3	95%	PERCENT
dti-3213	97	4	5.0 to 7.9	CARDINAL
dti-3213	97	5	1.0	CARDINAL
dti-3213	97	6	95%	PERCENT
dti-3213	97	7	2.5	CARDINAL
dti-3213	97	8	5.4	CARDINAL
dti-3213	97	9	95%	PERCENT
dti-3213	97	10	3.4 to 7.5	CARDINAL
dti-3213	97	11	1	CARDINAL
dti-3213	98	1	86420	CARDINAL
dti-3213	98	2	4.0	CARDINAL
dti-3213	98	3	95%	PERCENT
dti-3213	98	4	1.7 to	CARDINAL
dti-3213	98	5	6.2	CARDINAL
dti-3213	98	6	5.4	CARDINAL
dti-3213	98	7	95%	PERCENT
dti-3213	98	8	3.4 to 7.5	CARDINAL
dti-3213	98	9	1	CARDINAL
dti-3213	99	1	95%	PERCENT
dti-3213	99	2	baseline to 1 year	DATE
dti-3213	100	1	ranibizumab	PERSON
dti-3213	101	1	cst	ORG
dti-3213	101	2	cst	ORG
dti-3213	101	3	95%	PERCENT
dti-3213	101	4	−156.2	PERSON
dti-3213	101	5	−130.1	PERSON
dti-3213	101	6	95%	PERCENT
dti-3213	101	7	95%	PERCENT
dti-3213	102	1	2	CARDINAL
dti-3213	103	1	200	CARDINAL
dti-3213	103	2	95%	PERCENT
dti-3213	103	3	95%	PERCENT
dti-3213	103	4	2	CARDINAL
dti-3213	103	5	cst	ORG
dti-3213	103	6	95%	PERCENT
dti-3213	103	7	baseline to 1 year	DATE
dti-3213	104	1	cst	ORG
dti-3213	104	2	ranibizumab	PERSON
dti-3213	106	1	95%	PERCENT
dti-3213	106	2	4.4 to 7.4	CARDINAL
dti-3213	106	3	95%	PERCENT
dti-3213	106	4	0.4 to 3.5	CARDINAL
dti-3213	107	1	95%	PERCENT
dti-3213	107	2	1.7	CARDINAL
dti-3213	107	3	6.2	CARDINAL
dti-3213	107	4	0.0005	CARDINAL
dti-3213	108	1	cst	ORG
dti-3213	108	2	−71.5 μm	MONEY
dti-3213	109	1	95%	PERCENT
dti-3213	109	2	1	CARDINAL
dti-3213	109	3	2	CARDINAL
dti-3213	110	1	anti-vegf	ORG
dti-3213	110	2	italy	GPE
dti-3213	111	1	ipd	ORG
dti-3213	111	2	31	CARDINAL
dti-3213	111	3	30	CARDINAL
dti-3213	112	1	two	CARDINAL
dti-3213	112	2	irf	PERSON
dti-3213	112	3	srf	ORG
dti-3213	112	4	va	GPE
dti-3213	113	1	5.4	CARDINAL
dti-3213	113	2	95%	PERCENT
dti-3213	113	3	3.4 to 7.5	CARDINAL
dti-3213	113	4	cst	ORG
dti-3213	113	5	μm	CARDINAL
dti-3213	113	6	95%	PERCENT
dti-3213	114	1	95%	PERCENT
dti-3213	114	2	5.0 to 7.9	CARDINAL
dti-3213	114	3	weeks 40-48	DATE
dti-3213	114	4	30	CARDINAL
dti-3213	114	5	+1.0	NORP
dti-3213	114	6	95%	PERCENT
dti-3213	114	7	2.5	CARDINAL
dti-3213	114	8	+1.0	NORP
dti-3213	115	1	19.3	CARDINAL
dti-3213	115	2	31	CARDINAL
dti-3213	116	1	cst	ORG
dti-3213	116	2	95%	PERCENT
dti-3213	116	3	−71 μm	PRODUCT
dti-3213	117	1	95%	PERCENT
dti-3213	117	2	−84 to	CARDINAL
dti-3213	117	3	58	CARDINAL
dti-3213	117	4	weeks 40-48	DATE
dti-3213	118	1	95%	PERCENT
dti-3213	118	2	15	CARDINAL
dti-3213	119	1	anti-vegf	PERSON
dti-3213	119	2	median va	FAC
dti-3213	119	3	6	CARDINAL
dti-3213	119	4	31	CARDINAL
dti-3213	120	1	11,14,16,33	CARDINAL
dti-3213	121	1	9,10,13,15,17,34,35	CARDINAL
dti-3213	122	1	cst	ORG
dti-3213	122	2	cst	ORG
dti-3213	122	3	−71.5 μm	MONEY
dti-3213	124	1	first	ORDINAL
dti-3213	124	2	italy	GPE
dti-3213	125	1	first	ORDINAL
dti-3213	125	2	cst	ORG
dti-3213	125	3	anti-vegf soc	ORG
dti-3213	127	1	itc	ORG
dti-3213	127	2	faricimab	PERSON
dti-3213	127	3	italy110	GPE
dti-3213	127	4	2024	DATE
dti-3213	128	1	1177-3928	CARDINAL
dti-3213	128	2	cst	ORG
dti-3213	128	3	anti-vegf	ORG
dti-3213	131	1	at least two	CARDINAL
dti-3213	131	2	one	CARDINAL
dti-3213	131	3	around 52 weeks	DATE
dti-3213	131	4	only one	CARDINAL
dti-3213	132	1	va	GPE
dti-3213	132	2	cst	ORG
dti-3213	132	3	anti-vegf	NORP
dti-3213	132	4	ranibizumab	PERSON
dti-3213	135	1	roche s.p.a	ORG
dti-3213	136	1	ispor europe 2023	ORG
dti-3213	136	2	copenhagen	ORG
dti-3213	136	3	november 12-15	DATE
dti-3213	136	4	2023	CARDINAL
dti-3213	137	1	novartis	ORG
dti-3213	137	2	bayer	ORG
dti-3213	137	3	roche	ORG
dti-3213	137	4	zeiss	ORG
dti-3213	137	5	fv bayer	PERSON
dti-3213	137	6	novartis	ORG
dti-3213	137	7	roche	ORG
dti-3213	137	8	mn roche	ORG
dti-3213	137	9	sv abbvie	ORG
dti-3213	137	10	apellis	NORP
dti-3213	137	11	bayer	ORG
dti-3213	138	1	novartis	ORG
dti-3213	138	2	roche	ORG
dti-3213	138	3	roche	ORG
dti-3213	138	4	roche	ORG
dti-3213	138	5	roche	ORG
dti-3213	138	6	allergan	GPE
dti-3213	138	7	apellis	GPE
dti-3213	138	8	bausch & lomb	ORG
dti-3213	138	9	bayer, biogen	ORG
dti-3213	138	10	boehringer ingelheim	ORG
dti-3213	138	11	genentech	ORG
dti-3213	138	12	novartis	ORG
dti-3213	138	13	roche	ORG
dti-3213	142	1	1	CARDINAL
dti-3213	142	2	jm	ORG
dti-3213	142	3	buitendijk ghs	PERSON
dti-3213	142	4	european	NORP
dti-3213	143	1	europe	LOC
dti-3213	145	1	2017;124(12):1753-1763	DATE
dti-3213	146	1	2	CARDINAL
dti-3213	146	2	flaxman	PERSON
dti-3213	146	3	sr	ORG
dti-3213	146	4	bourne rra	PERSON
dti-3213	147	1	1990-2020	DATE
dti-3213	148	1	lancet	ORG
dti-3213	149	1	2017;5(12):e1221	CARDINAL
dti-3213	149	2	3	CARDINAL
dti-3213	150	1	steinmetz jd	PERSON
dti-3213	150	2	bourne rra	PERSON
dti-3213	150	3	briant ps	PERSON
dti-3213	151	1	2020	DATE
dti-3213	151	2	30 years	DATE
dti-3213	151	3	2020	DATE
dti-3213	152	1	lancet	ORG
dti-3213	153	1	2021;9(2):e144	CARDINAL
dti-3213	154	1	4	CARDINAL
dti-3213	154	2	ambati	PERSON
dti-3213	154	3	fowler	PERSON
dti-3213	156	1	2012;75(1):26-39	DATE
dti-3213	157	1	crossref	ORG
dti-3213	157	2	5	CARDINAL
dti-3213	158	1	cheung lk	PERSON
dti-3213	158	2	eaton a. age-	PERSON
dti-3213	160	1	2013;33(8):838-855	CARDINAL
dti-3213	161	1	6	CARDINAL
dti-3213	162	1	ferris fl iii	PERSON
dti-3213	162	2	wilkinson cp	PERSON
dti-3213	165	1	2013;120(4):844-851	CARDINAL
dti-3213	166	1	7	CARDINAL
dti-3213	167	1	mahdi l	ORG
dti-3213	170	1	2015;59(2):74	CARDINAL
dti-3213	171	1	8	CARDINAL
dti-3213	172	1	patel p	PERSON
dti-3213	172	2	sheth v.	PERSON
dti-3213	173	1	j clin med	PERSON
dti-3213	174	1	2021;10(11):2436	CARDINAL
dti-3213	174	2	9	CARDINAL
dti-3213	175	1	brown dm	PERSON
dti-3213	175	2	kaiser pk	PERSON
dti-3213	175	3	michels m	PERSON
dti-3213	176	1	ranibizumab versus verteporfin	PERSON
dti-3213	178	1	2006;355(14):1432-1444	CARDINAL
dti-3213	179	1	10	CARDINAL
dti-3213	180	1	busbee bg	PERSON
dti-3213	180	2	ho ac	PERSON
dti-3213	180	3	brown dm	PERSON
dti-3213	181	1	twelve-month	DATE
dti-3213	181	2	0.5 mg	QUANTITY
dti-3213	183	1	2013;120(5):1046-1056	CARDINAL
dti-3213	184	1	crossref	ORG
dti-3213	184	2	11	CARDINAL
dti-3213	185	1	cohen sy	PERSON
dti-3213	186	1	daily	DATE
dti-3213	188	1	481	CARDINAL
dti-3213	189	1	12	CARDINAL
dti-3213	190	1	dugel pu	PERSON
dti-3213	190	2	koh	PERSON
dti-3213	191	1	3	CARDINAL
dti-3213	193	1	2020;127(1):72-84	CARDINAL
dti-3213	194	1	13	CARDINAL
dti-3213	195	1	brown dm	PERSON
dti-3213	195	2	chong v	PERSON
dti-3213	195	3	1	CARDINAL
dti-3213	195	4	2	CARDINAL
dti-3213	196	1	intravitreal	PERSON
dti-3213	196	2	vegf trap-eye	PERSON
dti-3213	198	1	2012;119(12	CARDINAL
dti-3213	199	1	14	CARDINAL
dti-3213	200	1	holz fg	ORG
dti-3213	200	2	beatty s	PERSON
dti-3213	204	1	2015;99(2):220	CARDINAL
dti-3213	205	1	15	CARDINAL
dti-3213	206	1	rosenfeld pj	PERSON
dti-3213	206	2	brown dm	PERSON
dti-3213	207	1	ranibizumab	PERSON
dti-3213	209	1	2006;355(14):1419-1431	CARDINAL
dti-3213	210	1	https://doi.org/10.1056/nejmoa054481	PERSON
dti-3213	210	2	galeone et al	PERSON
dti-3213	210	3	2024	CARDINAL
dti-3213	210	4	18	CARDINAL
dti-3213	210	5	111	CARDINAL
dti-3213	210	6	2024	CARDINAL
dti-3213	211	1	16	CARDINAL
dti-3213	212	1	staurenghi g	PERSON
dti-3213	214	1	khetan	ORG
dti-3213	214	2	ed	PERSON
dti-3213	215	1	plos	PERSON
dti-3213	215	2	one	CARDINAL
dti-3213	216	1	2021;16(9):e0256461	CARDINAL
dti-3213	216	2	17	CARDINAL
dti-3213	217	1	martin df	PERSON
dti-3213	217	2	maguire mg	PERSON
dti-3213	217	3	ying gs	PERSON
dti-3213	217	4	grunwald je	PERSON
dti-3213	217	5	jaffe gj	PERSON
dti-3213	217	6	catt research group	ORG
dti-3213	218	1	ranibizumab	PERSON
dti-3213	220	1	2011;364(20):1897-1908	DATE
dti-3213	221	1	18	CARDINAL
dti-3213	222	1	calabria s	PERSON
dti-3213	222	2	dondi l	PERSON
dti-3213	223	1	maculare neovascolare correlata all’età	PRODUCT
dti-3213	223	2	anti-vegf attraverso	NORP
dti-3213	224	1	recenti prog med	ORG
dti-3213	225	1	2023;114(7):447	CARDINAL
dti-3213	225	2	461	CARDINAL
dti-3213	226	1	19	CARDINAL
dti-3213	227	1	kodjikian l	ORG
dti-3213	227	2	cohen sy	PERSON
dti-3213	228	1	europe	LOC
dti-3213	230	1	2179-2188	CARDINAL
dti-3213	231	1	crossref	ORG
dti-3213	231	2	20	CARDINAL
dti-3213	236	1	3561-3567	DATE
dti-3213	237	1	crossref	ORG
dti-3213	237	2	21	CARDINAL
dti-3213	242	1	2021;105(11	ORDINAL
dti-3213	242	2	1475-1479	DATE
dti-3213	243	1	22	CARDINAL
dti-3213	244	1	kertes pj	PERSON
dti-3213	244	2	greve m	PERSON
dti-3213	244	3	ranibizumab	PERSON
dti-3213	245	1	jama ophthalmol	PERSON
dti-3213	246	1	2020;138(3):244	CARDINAL
dti-3213	247	1	crossref	ORG
dti-3213	247	2	23	CARDINAL
dti-3213	248	1	kim	PERSON
dti-3213	248	2	mehta h	ORG
dti-3213	248	3	nguyen v	PERSON
dti-3213	248	4	gillies mc	PERSON
dti-3213	250	1	2016;36(8):1418	CARDINAL
dti-3213	251	1	24	CARDINAL
dti-3213	252	1	okada m	ORG
dti-3213	252	2	chong ew	PERSON
dti-3213	254	1	j ophthalmol	PERSON
dti-3213	255	1	2018;192	CARDINAL
dti-3213	255	2	184	CARDINAL
dti-3213	256	1	25	CARDINAL
dti-3213	257	1	silva r	PERSON
dti-3213	257	2	larsen m	PERSON
dti-3213	257	3	monés j	PERSON
dti-3213	258	1	monthly	DATE
dti-3213	258	2	ranibizumab	PERSON
dti-3213	260	1	2018;125(1):57-65	DATE
dti-3213	261	1	crossref	ORG
dti-3213	261	2	26	CARDINAL
dti-3213	262	1	wykoff cc	PERSON
dti-3213	262	2	clark wl	PERSON
dti-3213	262	3	nielsen	PERSON
dti-3213	262	4	brill jv	ORG
dti-3213	262	5	greene ls	PERSON
dti-3213	262	6	heggen	ORG
dti-3213	263	1	anti-vegf	PERSON
dti-3213	264	1	jmcp	PERSON
dti-3213	265	1	2018	DATE
dti-3213	266	1	27	CARDINAL
dti-3213	267	1	aifa	ORG
dti-3213	268	1	determina 2 ottobre 2023	PERSON
dti-3213	268	2	uso umano «	PERSON
dti-3213	268	3	10	CARDINAL
dti-3213	268	4	della legge	PERSON
dti-3213	268	5	24 dicembre 1993	DATE
dti-3213	268	6	n. 537	ORG
dti-3213	270	1	gu n.235 del 7-10-2023	PERSON
dti-3213	271	1	2023	CARDINAL
dti-3213	273	1	july 2024) 28	DATE
dti-3213	274	1	aifa	ORG
dti-3213	275	1	determina 28 dicembre 2020	ORG
dti-3213	275	2	istituzione della nota	ORG
dti-3213	275	3	98	CARDINAL
dti-3213	275	4	relativa alla prescrizione e alla somministrazione	ORG
dti-3213	275	5	di anti-vegf nella	ORG
dti-3213	275	6	amd e dme	PERSON
dti-3213	276	1	determina n. dg/1379/2020	PERSON
dti-3213	277	1	gu n.323 del 31-12-2020	PERSON
dti-3213	278	1	2020	DATE
dti-3213	280	1	july 2024) 29	DATE
dti-3213	281	1	aifa	ORG
dti-3213	282	1	determina	GPE
dti-3213	282	2	30	CARDINAL
dti-3213	282	3	inserimento di una	PERSON
dti-3213	282	4	terapeutica del medicinale	LOC
dti-3213	282	5	uso umano «bevacizumab	PERSON
dti-3213	282	6	648/1996	CARDINAL
dti-3213	282	7	modifica alla determina n. 622	PERSON
dti-3213	282	8	del 23	FAC
dti-3213	282	9	2014	DATE
dti-3213	282	10	della stessa	PERSON
dti-3213	283	1	determina n. 79/2015	ORG
dti-3213	284	1	gu n.38 del 16-2-2015	PERSON
dti-3213	285	1	2015	DATE
dti-3213	287	1	july 2024) 30	DATE
dti-3213	288	1	khanani am	PERSON
dti-3213	288	2	quezada ruiz c	PERSON
dti-3213	288	3	tenaya	GPE
dti-3213	289	1	every 16 weeks	DATE
dti-3213	289	2	two	CARDINAL
dti-3213	289	3	3	CARDINAL
dti-3213	290	1	lancet	ORG
dti-3213	291	1	2022;399(10326):729-740	CARDINAL
dti-3213	292	1	31	CARDINAL
dti-3213	293	1	parravano mc	PERSON
dti-3213	293	2	nicolo m	PERSON
dti-3213	294	1	italy	GPE
dti-3213	296	1	32	CARDINAL
dti-3213	297	1	chesnaye nc	PERSON
dti-3213	297	2	stel	ORG
dti-3213	299	1	clin kidney j. 2021;15(1):14-20	PERSON
dti-3213	300	1	33	CARDINAL
dti-3213	301	1	holz fg	ORG
dti-3213	301	2	beatty s	PERSON
dti-3213	301	3	anti-vegf	NORP
dti-3213	303	1	2016;30(8):1063-1071	CARDINAL
dti-3213	304	1	34	CARDINAL
dti-3213	305	1	li jq	PERSON
dti-3213	305	2	welchowski t	GPE
dti-3213	305	3	schmid m	ORG
dti-3213	305	4	mauschitz mm	PERSON
dti-3213	305	5	holz fg	ORG
dti-3213	306	1	europe	LOC
dti-3213	309	1	2020;104(8):1077-1084	CARDINAL
dti-3213	310	1	crossref	ORG
dti-3213	310	2	35	CARDINAL
dti-3213	311	1	r.	NORP
dti-3213	311	2	spain	GPE
dti-3213	313	1	385	CARDINAL
dti-3213	314	1	crossref pubmed https://doi.org/10.1371/journal.pone.0256461 https://pubmed.ncbi.nlm.nih.gov/34469431/	ORG
dti-3213	314	2	https://www.ncbi.nlm.nih.gov/pubmed/34053331 https://doi.org/10.1007/s00417-021-05451-2 https://www.ncbi.nlm.nih.gov/pubmed/34669026	QUANTITY
dti-3213	316	1	https://www.ncbi.nlm.nih.gov/pubmed/29885297	CARDINAL